The fund house believes that these are interesting times for Indian healthcare sector despite disappointing earnings in FY18. The sector has the potential to get re-rated after temporary disruptions get resolved

Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?

Finance Minister Arun Jaitley on Saturday presented his maiden full-year Budget for the 2015-16 financial year in the Lok Sabha. Read the full text of his speech here:

Many feel if the Bharatiya Janata Party (BJP) forms the next government, as is widely expected, it could mean an end to side-stepping on contentious issues at the cost of national interest.

The New Year offers great investment opportunities for retail investors as the country's economy looks to emerge from a prolonged lean phase. This is, therefore, time for investors to make smart decisions to reap the benefits of a reviving economy.

Although not all companies have declared results yet, based on the past trend - that is, Sensex earnings growth of just 6.8% in 2011-12 and 6.2% in 2012-13, and the results so far - double-digit growth looks difficult.

The Department of Pharmaceuticals has notified the Drugs (Prices Control) Order 2013, under which prices of 348 medicines have been brought under price control.

Prices of 348 medicines, including life saving drugs, will be cheaper soon by up to 80 per cent as the new Drug Price Control Order has come into effect.

Corporate America has sought major reforms in the country's health sector including foreign direct investment and global collaboration in life sciences.

The Planning Commission has set a target for the Indian pharmaceutical industry to reach $100 billion by 2020 and account for 5 per cent share of the global drug industry in the next five years.

A new drug price control policy, restrictions on multinationals taking over domestic firms and India cracking down on foreign firms' patents marked the year 2012 for the $22 billion pharmaceutical sector.

The National Pharmaceutical Pricing Policy 2012, which was cleared by the government in November, would bring 348 essential drugs under price control.

The government allowed 51 per cent foreign direct investment in multi-brand retail and 100 per cent in single-brand retail. This led to a rally in stocks of retail companies. Here's how reforms will impact stocks in other sectors where measures have been announced.